ALXO — ALX Oncology Holdings Inc. Dilution Risk Tracker

ALX Oncology Holdings Inc. (ALXO) has a DilutionScore of 38/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

ALXO has an active ATM (at-the-market) program with $117.8M remaining capacity. ATM programs allow companies to sell shares continuously into the open market through a broker-dealer — without announcing a secondary offering. This creates a silent but steady source of share dilution that shows up in quarterly share count increases rather than a discrete offering event. Cash runway is a key watch item: ALXO has approximately 15 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for ALXO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ALXO alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.